Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.
Duchnowska R, Biernat W, Szostakiewicz B, Sperinde J, Piette F, Haddad M, Paquet A, Lie Y, Czartoryska-Arłukowicz B, Wysocki P, Jankowski T, Radecka B, Foszczynska-Kłoda M, Litwiniuk M, Debska S, Weidler J, Huang W, Buyse M, Bates M, Jassem J. Duchnowska R, et al. Among authors: wysocki p. Oncologist. 2012;17(1):26-35. doi: 10.1634/theoncologist.2011-0212. Epub 2012 Jan 10. Oncologist. 2012. PMID: 22234627 Free PMC article.
Targeted therapy of renal cell cancer.
Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A. Wysocki PJ, et al. Curr Opin Investig Drugs. 2008 Jun;9(6):570-5. Curr Opin Investig Drugs. 2008. PMID: 18516756 Review.
Progress in the treatment of bone metastases in cancer patients.
Mackiewicz-Wysocka M, Pankowska M, Wysocki PJ. Mackiewicz-Wysocka M, et al. Expert Opin Investig Drugs. 2012 Jun;21(6):785-95. doi: 10.1517/13543784.2012.679928. Epub 2012 Apr 16. Expert Opin Investig Drugs. 2012. PMID: 22500564 Review.
Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arłukowicz B, Wysocki PJ, Foszczyńska-Kłoda M, Radecka B, Litwiniuk MM, Zok J, Wiśniewski M, Zuziak D, Biernat W, Jassem J. Duchnowska R, et al. Clin Cancer Res. 2014 May 15;20(10):2805-13. doi: 10.1158/1078-0432.CCR-13-2782. Epub 2014 Mar 25. Clin Cancer Res. 2014. PMID: 24668646
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.
Duchnowska R, Wysocki PJ, Korski K, Czartoryska-Arłukowicz B, Niwińska A, Orlikowska M, Radecka B, Studziński M, Demlova R, Ziółkowska B, Merdalska M, Hajac Ł, Myśliwiec P, Zuziak D, Dębska-Szmich S, Lang I, Foszczyńska-Kłoda M, Karczmarek-Borowska B, Żawrocki A, Kowalczyk A, Biernat W, Jassem J; Central and East European Oncology Group (CEEOG). Duchnowska R, et al. Among authors: wysocki pj. Oncotarget. 2016 Jan 5;7(1):550-64. doi: 10.18632/oncotarget.6375. Oncotarget. 2016. PMID: 26623720 Free PMC article.
Targeted therapy of hepatocellular cancer.
Wysocki PJ. Wysocki PJ. Expert Opin Investig Drugs. 2010 Feb;19(2):265-74. doi: 10.1517/13543780903514110. Expert Opin Investig Drugs. 2010. PMID: 20074016 Review.
143 results